Showing 1121-1130 of 7756 results for "".
Color Me Healthy: Patient-Centered Care in Skin of Color
https://practicaldermatology.com/topics/skin-cancer-photoprotection/color-me-healthy-patient-centered-care-in-skin-of-color/20778/Dermatologists' approaches to treating darker skin types aren't color blind…yet.Wise Investing
https://practicaldermatology.com/topics/practice-management/wise-investing/20666/The key to building wealth during today's bull markets, bear markets, and corrections.Backdoor Roth IRA Strategy
https://practicaldermatology.com/topics/practice-management/backdoor-roth-ira-strategy/20428/An effective step toward tax diversification.Histiocytoses: A Review of the Most Recent Classification System
https://practicaldermatology.com/topics/skin-cancer-photoprotection/histiocytoses-a-review-of-the-most-recent-classification-system/20503/A look at the proposed new classification system, grouping the histiocytoses into five categories, with tabular summaries for differential diagnosis.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuPipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigWeighing the Prospects of Biosimilars
https://practicaldermatology.com/columns/clinical-focus-1/weighing-the-prospects-of-biosimilars/21477/If they are found to be comparable to the “originators,” biosimilar agents may offer patients significant therapeutic benefits as well as cost efficiency.The Excoriated and Bleeding Edge: Updates in Eczema for the Clinician
https://practicaldermatology.com/topics/general-topics/the-excoriated-and-bleeding-edge-updates-in-eczema-for-the-clinician/21469/Atopic dermatitis continues to present treatment challenges, but a steady juggling of four main components—moisturization, antibiotics, anti-inflammatory, and antipruritics— help to maximize control of the disease.Cosmeceuticals: Sunscreens
https://practicaldermatology.com/topics/general-topics/cosmeceuticals-sunscreens/21366/What you should know about the FDA's final ruling on sunscreen products and tips for understanding the variety of sun protection ingredients available to make more informed recommendations to patients.Wardrobe
Malfunctionhttps://practicaldermatology.com/topics/practice-management/wardrobe-malfunction/20913/Top dermatologists share tips on dressing for success.